Figure 3. Association of Immune Checkpoint Inhibitors With Overall Survival and Progression-Free Survival.

Cox hazard ratios (HRs), Cox-Taylor expansion adjustment for short-term survival data (Cox-TEL) HRs (ST-HR), and difference in proportions of survival probability for long-term survivors (LT-DP) illustrate survival end points of included studies before and after Cox-TEL adjustment for overall survival (A) and progression-free survival (B). Pooled end points are meta-analysis results. The weight for each study is inversely proportional to the within-study variance of log(HR) plus the between-studies variance. NSCLC indicates non–small cell lung cancer; UC, urothelial carcinoma.